Comprehensive Analysis of CCAAT/Enhancer Binding Protein Family in Ovarian Cancer.

Biomarker CCAAT/enhancer binding protein drug responsiveness ovarian cancer survival

Journal

Cancer informatics
ISSN: 1176-9351
Titre abrégé: Cancer Inform
Pays: United States
ID NLM: 101258149

Informations de publication

Date de publication:
2024
Historique:
received: 02 05 2024
accepted: 28 07 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: epublish

Résumé

Ovarian cancer has brought serious threats to female health. CCAAT/enhancer binding proteins (C/EBPs) are key transcription factors involved in ovarian cancer. Therefore, comprehensive profiling C/EBPs in ovarian cancer is needed. A comprehensive analysis concerning C/EBPs in ovarian cancer was performed. Firstly, detailed expression of C/EBP family members was integrally retrieved and then confirmed using immunohistochemistry. The regulatory effects and transcription regulatory functions of C/EBPs were studied by using regulatory network analysis and enrichment analysis. Using survival analysis, receiver operating characteristic curve analysis, and target-disease association analysis, the predictive prognostic value of C/EBPs on survival and drug responsiveness was systematically evaluated. The effects of C/EBPs on tumor immune infiltration were also assessed. Ovarian cancer tissues expressed increased CEBPA, CEBPB, and CEBPG but decreased CEBPD when compared with normal control tissues. The overall alteration frequency of C/EBPs in ovarian cancer was approaching 30%. C/EBP family members formed a reciprocal regulatory network involving carcinogenesis and had pivotal transcription regulatory functions. C/EBPs could affect survival of ovarian cancer and correlated with poor survival outcomes (OS: HR = 1.40, P = .0053 and PFS: HR = 1.41, P = .0036). Besides, expression of CEBPA, CEBPB, CEBPD, and CEBPE could predict platinum and taxane responsiveness of ovarian cancer. C/EBPs also affected immune infiltration of ovarian cancer. C/EBPs were closely involved in ovarian cancer and exerted multiple biological functions. C/EBPs could be exploited as prognostic and predictive biomarkers in ovarian cancer.

Sections du résumé

Background UNASSIGNED
Ovarian cancer has brought serious threats to female health. CCAAT/enhancer binding proteins (C/EBPs) are key transcription factors involved in ovarian cancer. Therefore, comprehensive profiling C/EBPs in ovarian cancer is needed.
Methods UNASSIGNED
A comprehensive analysis concerning C/EBPs in ovarian cancer was performed. Firstly, detailed expression of C/EBP family members was integrally retrieved and then confirmed using immunohistochemistry. The regulatory effects and transcription regulatory functions of C/EBPs were studied by using regulatory network analysis and enrichment analysis. Using survival analysis, receiver operating characteristic curve analysis, and target-disease association analysis, the predictive prognostic value of C/EBPs on survival and drug responsiveness was systematically evaluated. The effects of C/EBPs on tumor immune infiltration were also assessed.
Results UNASSIGNED
Ovarian cancer tissues expressed increased CEBPA, CEBPB, and CEBPG but decreased CEBPD when compared with normal control tissues. The overall alteration frequency of C/EBPs in ovarian cancer was approaching 30%. C/EBP family members formed a reciprocal regulatory network involving carcinogenesis and had pivotal transcription regulatory functions. C/EBPs could affect survival of ovarian cancer and correlated with poor survival outcomes (OS: HR = 1.40, P = .0053 and PFS: HR = 1.41, P = .0036). Besides, expression of CEBPA, CEBPB, CEBPD, and CEBPE could predict platinum and taxane responsiveness of ovarian cancer. C/EBPs also affected immune infiltration of ovarian cancer.
Conclusions UNASSIGNED
C/EBPs were closely involved in ovarian cancer and exerted multiple biological functions. C/EBPs could be exploited as prognostic and predictive biomarkers in ovarian cancer.

Identifiants

DOI: 10.1177/11769351241275877 PMID: 39238655 PMC: PMC11375656
pubmed: 39238655
doi: 10.1177/11769351241275877
pii: 10.1177_11769351241275877
pmc: PMC11375656
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11769351241275877

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Jiahong Tan (J)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.
ORCID: 0000-0002-5748-4697

Daoqi Wang (D)

Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
ORCID: 0000-0002-6098-9477

Wei Dong (W)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Lei Nian (L)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Fen Zhang (F)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Han Zhao (H)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Jie Zhang (J)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Yun Feng (Y)

Department of Obstetrics and Gynecology, National Key Clinical Specialty of Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Classifications MeSH